Clinical Trial

Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

Study acronym: BRICKET
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 5, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to evaluate the activity, in terms of best response according to RECIST criteria 1.1 as assessed by the local investigator, of the ctDNA-guided retreatment with encorafenib plus cetuximab in BRAFV600E mutated mCRC patients experiencing benefit from previous exposure to encorafenib plus cetuximab (+/- chemotherapy) and with BRAFV600E mutated, KRAS, NRAS and MAP2K1 wild-type and MET not amplified status on ctDNA at the time of study entry.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2024-08-27; most recent amendment 2025-12-30.
Status change: Recruiting → Active, Not Recruiting 2025-12-30
Trial Details
NCT Number NCT06578559
Lead Sponsor Gruppo Oncologico del Nord-Ovest
Collaborators: Merck Sharp & Dohme LLC, Pierre Fabre Laboratories
Conditions Colorectal Cancer
Enrollment 16 participants
Start Date 2024-07-23
Primary Completion 2026-08-01 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-05